Antengene collaborates with WuXi Biologics in developing innovative oncology drugs.
Wuxi Biologics and Antengene Corporation recently announced that both companies will be collaborating to develop and produce novel drugs, and jointly promote the R&D of innovative oncology therapies.
Wuxi Biologics offers end-to-end solutions based on its robust R&D system and technology platform to advance the process of promoting drug R&D from concept to commercial manufacturing.
Through the collaboration, WuXi Biologics and Antengene will be using their extensive resources and capabilities to accelerate the research and development of therapies and provide patients with high-quality yet affordable treatments.
FDA grants Direct Biologics more access for ExoFlo in the treatment of COVID-19 patients
Direct Biologics announced earlier this week that the FDA (Food and Drug Administration) has granted expanded access for ExoFlo in the treatment of patients with COVID-19 associated acute respiratory distress syndrome (ARDS).
While the company enrols patients in its Phase II, placebo controlled, randomized clinical trial, the new expanded access protocol will make ExoFlo available to a wider group of patients with severe COVID-19.
This approval comes under the multiple approvals for single patient Emergency Investigational New Drug (eIND) applications granted in September and October, of which physicians can obtain rapid approval to administer medication to a single patient through a direct appeal to the agency.
Eli Lilly holds its clinical trials on its Monoclonal Antibody COVID-19 treatment.
Eli Lilly said that they will be holding the clinical trial of its combination antibody treatment for COVID-19 due to safety reasons.
The clinical trial, evaluating Lilly’s investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Eli Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.
Eli Lilly is currently testing a combination of two lab-engineered immune system proteins called monoclonal antibodies to treat severely ill patients with COVID-19.
The monoclonal antibody treatment is said to give the immune system a head start on fighting the virus. The antibodies were demonstrated to home in on the SARS-COV-2 virus, neutralize it, and infuse it.